Skip to content

Top Stories

Top Stories

Primary Menu
  • Breaking News
  • UNIT CONVERTER
  • QR Code Generator
  • SEO META TAG GENERATOR
  • Background Remover Tool
  • Image Enhancer Tool
  • Image Converter Tool
  • Image Compressor Tool
  • Keyword Research Tool
  • Paint Tool
  • About Us
  • Contact Us
  • Privacy Policy
HOME PAGE
  • Home
  • Uncategorized
  • CVS strikes a deal to offer Wegovy at a discount
  • Uncategorized

CVS strikes a deal to offer Wegovy at a discount

VedVision HeadLines May 1, 2025
CVS strikes a deal to offer Wegovy at a discount


  • Customers at CVS will be able to buy weight loss drug Wegovy at a discount. Cash purchasers can get the Novo Nordisk made product for $499 per month. The pharma company has also recently struck deals with major telehealth companies.

CVS and Novo Nordisk have struck a deal that will see the drug-store chain offering the Wegovy weight-loss drug to customers at a discount.

Approximately 9,000 CVS locations will begin selling Wegovy for $499 per month to customers who pay cash out of pocket. That’s the same rate Novo Nordisk has offered previously through its online pharmacy.

Novo Nordisk has been looking for ways to expand its market share lately. It also recently aligned itself with telehealth companies Hims & Hers, Ro and LifeMD to sell Wegovy at a discount for cash customers.

“As the leader in obesity care for more than a decade, it is our responsibility to continue to work with others across the US healthcare system to find innovative opportunities to meet the needs of these patients and connect them with … Wegovy in a convenient and affordable way,” Dave Moore, president of Novo Nordisk, said in a statement.

Wegovy trails Ozempic in market share. Both drugs are made by Novo Nordisk.

The announcement comes as CVS exceeded analyst expectations in its first-quarter earnings. The company reported earnings per share of $2.25, versus a projected $1.70. Those numbers, however, did not include charges tied to a recent jury verdict against the company’s Omnicare program, which found the unit has filed false claims with Medicare, Medicaid and Tricare, resulting in damages of over $135.5 million.

The company also raised its 2025 guidance to a range of $6 to $6.20 in earnings per share, up from $5.75 to $6.

This story was originally featured on Fortune.com



Source link

Continue Reading

Previous: Victoria Derbyshire, 56, says ‘bully’ father ‘strangled’ and ‘pulled her out of bed’ as she bravely shares abuse ordeal
Next: How to Save Time and Money at the Airport

Related News

What’s Behind the Massive .6 Billion in Ethereum Unstaking?
  • Uncategorized

What’s Behind the Massive $2.6 Billion in Ethereum Unstaking?

VedVision HeadLines July 27, 2025
SMCI Stock Trade Surge Sparks Bullish Catalysts
  • Uncategorized

SMCI Stock Trade Surge Sparks Bullish Catalysts

VedVision HeadLines July 27, 2025
Former Binance CEO’s Alleged Support For Trump Initiatives: A Strategy For Pardon?
  • Uncategorized

Former Binance CEO’s Alleged Support For Trump Initiatives: A Strategy For Pardon?

VedVision HeadLines July 27, 2025

Recent Posts

  • Danish Kaneria targets Indian players after Asia Cup announcement
  • 26.34 lakh ‘ineligible’ beneficiaries will be temporarily suspended under Ladki Bahin scheme
  • UPSC aspirant debarred for 3 years for using unfair means during govt job exam | Education News
  • What’s Behind the Massive $2.6 Billion in Ethereum Unstaking?
  • Moulika Arabhi on shaping India’s environmental laws

Recent Comments

No comments to show.

Archives

  • July 2025
  • June 2025
  • May 2025
  • April 2025

Categories

  • Current Affairs
  • Shopping
  • Uncategorized

You may have missed

Danish Kaneria targets Indian players after Asia Cup announcement
  • Current Affairs

Danish Kaneria targets Indian players after Asia Cup announcement

VedVision HeadLines July 27, 2025
26.34 lakh ‘ineligible’ beneficiaries will be temporarily suspended under Ladki Bahin scheme
  • Current Affairs

26.34 lakh ‘ineligible’ beneficiaries will be temporarily suspended under Ladki Bahin scheme

VedVision HeadLines July 27, 2025
UPSC aspirant debarred for 3 years for using unfair means during govt job exam | Education News
  • Current Affairs

UPSC aspirant debarred for 3 years for using unfair means during govt job exam | Education News

VedVision HeadLines July 27, 2025
What’s Behind the Massive .6 Billion in Ethereum Unstaking?
  • Uncategorized

What’s Behind the Massive $2.6 Billion in Ethereum Unstaking?

VedVision HeadLines July 27, 2025
Copyright © All rights reserved. | MoreNews by AF themes.